KA follows the unique practice of including a patient number in their bulletin. Earlier, KA used to publish individual new cases with patient no. which was useful to trace contacts from a case as well as follow through the entire patient lifecycle.
1/4
As cases increased, KA dropped publishing individual new cases in the bulletins but continues to publish the patient numbers for recoveries and deaths. While this is non-consequential to a lay person, this unique patient identifier was very useful to analysts.
2/4
How was the unique identifier useful?
* Helped calculate exact recovery characteristics based on demographic parameters. For eg. is duration for recovery dependent on age or symptoms?
* Helped draw a map of contact cases by interlinking primary and secondary contacts.
3/4
While patient numbers for recoveries and deaths without knowing the patient number of new cases does not help anymore, this practice that was followed by KA will remain to be an excellent example of data management and reporting during the pandemic.
4/4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
What will happen to covid19india.org after October 31st? Some pointers:
* There will be no data updates from 1st Nov, 2021 (sigh!).
* The website will be up and available for referencing past data.
* The website/operations are not being handed over to any group.
1/4
* Our team will wind down and we will be limiting our interactions on email and twitter. We will monitor communications occassionally and will try to respond to critical messages.
* With minimal involvement, we are constrained to respond to requests for interviews/talks.
2/4
* Why don't you convert the website to track broader health data?
This is an audacious goal, but our team is not invested into public health. Our work is open sourced. Groups with interest in public health can utilise our code to build broader public health data platforms.
3/4
Latest data from @PHE_uk on vaccine efficacy (VE) against HOSPITALISATION for the Delta variant.
VE for Covishield against hospitalisation:
✅ After 1 dose: 71%
✅ After 2 doses: 92%
❓Wasn't the reported efficacy lower against Delta? What has changed?
1/4
Vaccine efficacy can be measured against different endpoints. There can be efficacy against hospitalisation, against death, against symptomatic infection etc.
Earlier studies from the UK, had reported VE against SYMPTOMATIC INFECTION.
This is VE against hospitalisation.
2/4
Putting both these studies together:
VE for Covishield towards Delta variant:
✅ After 1 dose:
📌 Against symptomatic infection: 33%
📌 Against hospitalisation: 71%
✅ After 2 doses:
📌Against symptomatic infection: 60%
📌 Against hospitalisation: 92%
3/4
On breakthrough infections, vaccines and gap between doses:
A correspondence published in NEJM on 2nd June, details a study on breakthrough infections with a large cohort of 7000+ healthcare workers in a tertiary hospital in India.
7000+ received the first dose and 3600+ of them subsequently got the 2nd dose.
Vaccine administered was Covishield.
An additional 5000+ were not vaccinated.
Study period: Jan-Apr 2021.
📌 506 HCWs tested +ve during the study, of which 64% were unvaccinated.
2/n
📌 Of the 7000+ HCWs that got the 1st dose, only 2.6% of them tested positive.
📌 3600+ HCWs got both doses and 2% of them tested positive.
📌 Breakthrough infection, measured as those testing positive 14 days after both doses stood at 1.6%.
3/n
If you do not have any symptoms 14 days after confirmation of Covid, a repeat test IS NOT required.
1/n
❓When can I consider myself recovered from Covid?
➡️ 14 days after date of test.
➡️ 3 consecutive days of no symptoms.
➡️ If you had severe symptoms, consult your doctor for discharge criteria.
➡️ No need for a repeat RTPCR test.
2/n
❓Do I need to continue wearing masks inside my home after recovery?
No. One does not generally transmit the virus after Day 10 of infection. After 14 days of room quarantine, there is no need to wear a #mask inside the house.
3/n
A quick overview of Biological E.'s Covid vaccine:
✅ Vaccine platform: Protein Subunit.
✅ Number of doses: 2 doses
✅ Gap between doses: 28 days*
✅ Current status: Completed Phase 1 and 2 trials. Got approval for Phase 3 trials in April 2021.
*As per clinical trials.
1/n
✅ Partnership: Antigen developed by Texas Children's Hospital for Vaccine Development and Baylor College of Medicine. Adjuvant supplied by Dynavax Technologies (US).
✅ Proven platform used for Hepatitis B vaccine. Novavax vaccine also uses subunit technology.
2/n
✅ What is a protein subunit vaccine?
It consists of specific parts of the SARS-Cov-2 antigen that are synthesized and harvested in a medium like yeast. The proteins themselves elicit weak immune response and they need an adjuvant added to augment the immune response.